The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The market expects ANI Pharmaceuticals (ANIP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Some 20 travel staff at the FDA, who made arrangements for the regulator’s inspectors, will be getting their jobs back, as ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...